TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, announced that a poster featuring its lead therapeutic candidate, TTX-MC138, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on Oct. 23 in Madrid, Spain. The presentation will highlight the latest clinical update from the Phase 1a trial evaluating TTX-MC138 in patients with advanced solid tumors.
TTX-MC138 is an investigational therapeutic designed to target miR-10b, a microRNA associated with metastatic disease progression. The company’s focus on this biomarker is central to its approach, as miR-10b is a well-documented indicator of metastasis. By targeting miR-10b, TransCode aims to address metastatic tumors that overexpress this microRNA, potentially offering a new treatment option for patients with advanced disease.
The ESMO Congress is a significant venue for presenting oncology research, and TransCode’s selection to present updated Phase 1a data underscores the ongoing interest in its RNA-targeting platform. The Phase 1a trial is evaluating TTX-MC138 in patients with advanced solid tumors, and the upcoming presentation will provide the latest clinical update on the candidate’s safety and activity. For a clinical-stage company, such data readouts are critical milestones that can inform future development decisions and attract investor attention.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. In addition to TTX-MC138, the company has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The upcoming ESMO presentation represents an opportunity for TransCode to share its progress with the medical and scientific community, potentially raising awareness of its pipeline among key stakeholders.
For investors and industry observers, the presentation could provide validation of the company’s RNA-targeting approach and offer insights into the drug’s potential. The full press release can be viewed at https://nnw.fm/sGqsS, and the latest news and updates relating to RNAZ are available in the company’s newsroom at https://nnw.fm/RNAZ.
The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, delivering services that include wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and press release enhancement to ensure maximum impact.
The broader implications of TransCode’s presentation extend to the oncology community, where RNA-based therapies are an emerging area of research. If TTX-MC138 demonstrates a favorable profile in the Phase 1a trial, it could bolster confidence in microRNA-targeting strategies for metastatic cancers. Moreover, the data may help inform the design of subsequent trials and potentially accelerate the development of new treatments for patients with limited options. As the ESMO Congress 2026 approaches, the presentation will be closely watched by researchers, clinicians, and investors alike, given its potential to shape the future of RNA therapeutics in oncology.
